This is being announced and might be mis-understood by some. It...

This is being announced and might be mis-understood by some. It is not competing against PAB, but, "could" make a super partnership???
The interim results suggest that CLTX CAR T was generally well tolerated, with no dose limiting
toxicities (DLT’s), no Cytokine Release Syndrome (CRS) and no Tumor Lysis Syndrome (TLS).
Grade 3 events were generally manageable and most often attributed to disease progression.
“The CLTX CAR T dose escalation preliminary data are truly encouraging and have exceeded our
expectations, particularly given that the patients enrolled were heavily pretreated and very late
stage,” said Jennifer Chow, CEO and Managing Director of Chimeric Therapeutics.
“Historical therapies for recurrent Glioblastoma have generally been studied in patients with a
median of 1 prior line of therapy. In contrast, the CLTX CAR T study enrolled patients with a
median of 3 prior lines of therapy. The disease control rate of 55% is beyond that observed in
patients treated with 2nd line therapy in historical clinical trials".